Chemokine Therapeutics Receives Approval From Health Canada to Commence Phase II Study in Liver Cancer
Advertisement
Chemokine Therapeutics Corp. announced that it has received a No Objection Letter from Health Canada allowing the Company to begin a Phase II study in liver cancer with its lead drug candidate, CTCE-9908. The Company also recently received FDA approval for the study.
The Phase II trial will be an international, multi-centre, randomized, controlled, open label study assessing the efficacy and safety of CTCE-9908 that will include up to 123 patients. The primary end point will be to determine the response rate of tumours in patients with liver cancer treated with CTCE-9908 following transarterial chemoembolization (TACE) (a therapy used for non-resectable liver cancer) compared with patients receiving TACE alone. The Company will follow patients to also determine progression free survival, overall survival, as well as various tumour and angiogenic factors.